drugset / Trial / NCT06745531
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
RandomizedParallel-groupTriple-blindTreatment
Summary
A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
Timeline
- Start
- 2025-01-06
- Primary completion
- 2025-10-13
- Completion
- 2025-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TS-172 | Unknown | 20 mg | Oral |
| Subject | TS-172 | Unknown | 60 mg | Oral |